Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bioengineering of coagulation factor VIII for improved secretion.

Hongzhi Z Miao1, Nongnuch Sirachainan, Lisa Palmer

  • 1Department of Pediatrics, Howard Hughes Medical Institute, University of Michigan Medical Center, Ann Arbor, MI 48109, USA.

Blood
|January 17, 2004
PubMed
Summary

Bioengineering strategies significantly enhance Factor VIII (FVIII) production for hemophilia A gene therapy. Modified FVIII shows 15- to 25-fold greater secretion, improving recombinant protein manufacturing and therapeutic potential.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Screening of hereditary elliptocytosis caused by <i>SPTB</i> mutations and identification of its association with significant jaundice among Thai neonates.

BMJ paediatrics open·2026
Same author

Coordinated expression and assembly of BiP, p58<sup>IPK</sup>, and ER chaperone complexes maximize proinsulin folding in pancreatic β cells.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

An international survey on current practices of management of neonatal catheter-associated venous thromboembolism: communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Outcomes of hematopoietic stem cell transplantation for pediatric patients with transfusion-dependent thalassemia in Thailand.

Clinical and experimental pediatrics·2026
Same author

Activated ATF6α is a hepatic tumour driver restricting immunosurveillance.

Nature·2026
Same author

Factor VIII originates primarily from anatomically distinct subsets of liver sinusoidal endothelial cells.

Blood advances·2026

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Gene Therapy

Background:

  • Factor VIII (FVIII) is crucial for blood coagulation; deficiencies cause hemophilia A.
  • Recombinant FVIII production and gene therapy are hindered by low expression efficiency.
  • FVIII expression is limited by mRNA instability, ER chaperone interactions, and inefficient ER-to-Golgi transport.

Purpose of the Study:

  • To bioengineer Factor VIII for enhanced secretion and improved production efficiency.
  • To overcome limitations in recombinant FVIII production for hemophilia A treatment.
  • To develop strategies for more successful FVIII gene therapy.

Main Methods:

  • Engineered B-domain-deleted (BDD)-FVIII for higher mRNA levels.
  • Introduced point mutations in the A1 domain to reduce ER chaperone binding.

Related Experiment Videos

  • Engineered asparagine-linked oligosaccharides in the B-domain spacer to enhance ER-to-Golgi transport.

    • Main Results:

    • The bioengineered FVIII demonstrated 15- to 25-fold increased secretion efficiency in vitro and in vivo.
    • The modified FVIII overcomes key limitations in recombinant protein expression.
    • Improved secretion facilitates potential success in hemophilia A gene therapy.

    Conclusions:

    • Bioengineered FVIII significantly enhances secretion, addressing major production challenges.
    • This approach holds promise for improving recombinant FVIII manufacturing and hemophilia A gene therapy outcomes.
    • Targeted modifications offer a viable strategy for boosting therapeutic protein expression.